Year: 2022

TORONTO, Oct. 04, 2022 (GLOBE NEWSWIRE) — Centerra Gold Inc. (TSX: CG) (NYSE: CGAU) (“Centerra” or the “Company”) is pleased to announce that, subject to the approval of the Toronto Stock Exchange (“TSX”), it intends to proceed with a normal course issuer bid (“NCIB”) to purchase for cancellation up to an aggregate of 15,610,813 common shares in the capital of the Company (“Common Shares”), representing approximately 7.1% of Centerra’s total issued and outstanding Common Shares, or 10% of the public float. As of September 30, 2022, Centerra had 220,086,775 issued and outstanding Common Shares. Centerra believes that the Common Shares have been trading in a price range which does not adequately reflect the value of such shares in relation to Centerra’s assets and its future prospects. As a result, Centerra believes that the NCIB...

Downing Strategic Micro-Cap Investment Trust Plc (the “Company”)LEI: 213800QMYPUW4POFFX69Compliance with Market Abuse Regulation4 October 2022 The Company announces that, following the announcement of its net asset value as at 30 September 2022 on 3 October 2022, it is satisfied that all inside information which the Directors and the Company may have in the closed period (as defined by the EU Market Abuse Regulation) which ends on the date of the announcement of the Half Yearly results for the 6 months ended 31 August 2022 has been notified to a Regulated Information Service (“RIS”). The Company is therefore not prohibited from purchasing its own securities (“share buybacks”) during this period. For the duration of the closed period, the Company has given authority to its broker, finnCap, to undertake share buybacks...

To Nasdaq Copenhagen Peter Kjærgaard is leaving Nykredit Bank’s Executive Board Peter Kjærgaard, Head of Nykredit Wealth Management and member of Nykredit Bank’s Executive Board, has resigned his position effective today as he has accepted a new position outside the Nykredit Group. Peter Kjærgaard will also leave his positions as Chair of Nykredit Portefølje Administration A/S and Director of Sparinvest Holdings SE. Peter Kjærgaard joined the Nykredit Group in 2013 and has held the position as Head of Nykredit Wealth Management since 2019. Nykredit Wealth Management has delivered growth for many years now, and the business area is one of Nykredit’s strategic priorities. Group Chief Executive Michael Rasmussen says: ”I would naturally have preferred that Peter had continued the strong development and growth path that he and...

Frontline Ltd. (“Frontline” or “the Company”) announces the appointment of Mr. Marios Demetriades as a Director of the Company. Marios Demetriades is an experienced Financial Services professional with significant experience as a Non-Executive Director in various listed and private companies in the Banking, Infrastructure and Shipping industries. He previously served as the Minister of Transport, Communications and Works for the Republic of Cyprus from 2014 to 2018 and held various positions in the Accounting, Investment and Banking sectors. He is a qualified Chartered Accountant and Chartered Financial Analyst holder and a member of the CFA Institute, the Institute of Chartered Accountants in England and Wales and the Institute of Certified Public Accountants of Cyprus (ICPAC). Mr. Demetriades is a Cypriot citizen and resides in Cyprus. October...

Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2. These patients with HER2 low status may now be eligible for a targeted treatment, which could significantly improve their outcomes.1,2 The PATHWAY anti-HER2 (4B5) test is the only FDA approved companion diagnostic indicated as an aid in the assessment of HER2 low status in metastatic breast cancer patients. These patients may now consider ENHERTU as a treatment option based on the results of the Phase 3 DESTINY-Breast04 trial.3Basel, 4 October 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) approved the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody* to identify metastatic breast cancer patients with low HER2 expression for whom ENHERTU® (fam-trastuzumab deruxtecan-nxki)...